Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances) · 345.2M shares · +18%/yr ↑ dilution · EDGAR filings ↗
Reference price $2.31 · est. market cap ~$797M — last insider sale, 2026-04-21 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — allogeneic CAR-T clinical, heavy burn ($150M), funded.
Strengths
- Liquidity — current ratio 7.9 (73rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Chronic dilutionShare count +18%/yr over 4y (dilution, book value/share -84%)
- Cash burnNegative free cash flow (-149.6M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Insider sellingInsider selling — 12 open-market sale(s) by 6 insider(s) (cluster of 6 insiders, ~$556,197, last 6mo) Form 4 ↗
- Revenue declineRevenue -100.0% YoY
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-65.3%
Return on assets
-45.9%
Revenue growth (QoQ)
-100.0%
Current ratio
7.9×
Free cash flow
-$150M
EBITDA
-$197M
Tangible book value
$293M
Cash & investments
$266M
Cash runway
7q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-18 | Kazam Joshua A | Option exercise | 48K | — |
| 2026-04-21 | Yoshiyama Annie | Sell | 9.6K | $2.31 |
| 2026-03-31 | Beneski Benjamin Machinas | Sell | 2.9K | $2.50 |
| 2026-03-16 | Beneski Benjamin Machinas | Sell | 4.8K | $2.47 |
| 2026-03-16 | Chang David D | Sell | 48K | $2.47 |
| 2026-03-02 | Beneski Benjamin Machinas | Sell | 7.1K | $2.60 |
| 2026-02-02 | Beneski Benjamin Machinas | Sell | 7.5K | $1.73 |
| 2026-02-02 | Chang David D | Sell | 95K | $1.80 |
| 2026-02-02 | Parker Geoffrey M. | Sell | 24K | $1.76 |
| 2026-02-02 | Yoshiyama Annie | Sell | 4.2K | $1.72 |
| 2026-02-02 | Roberts Zachary | Sell | 36K | $1.77 |
| 2026-02-02 | Douglas Earl Martin | Sell | 23K | $1.76 |
| 2026-01-21 | Roberts Zachary | Sell | 26K | $1.56 |
| 2025-12-18 | Kazam Joshua A | Option exercise | 48K | — |
| 2025-11-17 | Beneski Benjamin Machinas | Sell | 786 | $1.22 |
| 2025-10-21 | Parker Geoffrey M. | Sell | 37K | $1.26 |
| 2025-06-10 | MESSEMER DEBORAH M. | Sell | 37K | $1.42 |
| 2025-04-21 | Yoshiyama Annie | Sell | 9.6K | $1.41 |
| 2025-03-14 | Chang David D | Sell | 47K | $1.96 |
| 2025-03-14 | Beneski Benjamin Machinas | Sell | 5.5K | $1.98 |
| 2025-03-01 | Beneski Benjamin Machinas | Grant | 32K | — |
| 2025-02-18 | MESSEMER DEBORAH M. | Sell | 13K | $2.43 |
| 2025-02-03 | Douglas Earl Martin | Sell | 6.4K | $1.71 |
| 2025-02-03 | Parker Geoffrey M. | Sell | 4.4K | $1.73 |
| 2025-02-03 | MOORE TIMOTHY L. | Sell | 15K | $1.71 |
| 2025-02-03 | Chang David D | Sell | 46K | $1.68 |
| 2025-02-03 | Roberts Zachary | Sell | 19K | $1.70 |
| 2025-01-24 | Douglas Earl Martin | Grant | 145K | — |
| 2025-01-24 | Parker Geoffrey M. | Grant | 174K | — |
| 2025-01-24 | Yoshiyama Annie | Grant | 36K | — |
| 2025-01-24 | Roberts Zachary | Grant | 174K | — |
| 2025-01-24 | Belldegrun Arie | Grant | 370K | — |
| 2025-01-24 | Chang David D | Grant | 552K | — |
| 2025-01-21 | Roberts Zachary | Sell | 27K | $1.78 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06500273 ↗ | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Large B-cell Lymphoma | PHASE2 | Recruiting | 2027-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-22 | 2026-06-18 | 0001628280-26-044618 ↗ |
| 8-K | 2026-05-28 | 2026-05-28 | 0001193125-26-245484 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001628280-26-034585 ↗ |
| 8-K | 2026-05-13 | 2026-05-12 | 0001628280-26-034583 ↗ |
| 8-K | 2026-04-15 | 2026-04-14 | 0001193125-26-157140 ↗ |
| 8-K | 2026-04-13 | 2026-04-13 | 0001193125-26-151999 ↗ |
| 8-K | 2026-04-13 | 2026-04-13 | 0001193125-26-152866 ↗ |
| 8-K | 2026-03-12 | 2026-03-12 | 0001628280-26-017230 ↗ |
| 10-K | 2026-03-12 | 2025-12-31 | 0001628280-26-017242 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001628280-25-050230 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001628280-25-050227 ↗ |
| 8-K | 2025-10-14 | 2025-09-26 | 0001628280-25-044828 ↗ |